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SKIN	  CANCER	  OUTCOMES	  AS	  A	  FUNCTION	  OF	  REFERRAL	  REASON	  IN	  SOLID	  
ORGAN	  TRANSPLANT	  RECIPIENTS.	  Sakil	  Chundydyal,	  Fang-­‐Yong	  Li,	  Oscar	  R.	  
Colegio,	  Department	  of	  Dermatology,	  Yale	  School	  of	  Medicine,	  New	  Haven,	  CT.	  	  	  
	  
Purpose	  of	  study:	  The	  purpose	  of	  this	  study	  is	  to	  examine	  the	  reason	  for	  referral	  of	  
Organ	  Transplant	  Recipients	  (OTR)	  to	  a	  specialized	  dermatology	  clinic	  as	  a	  
predictor	  of	  Non	  Melanoma	  Skin	  Cancer	  outcomes	  in	  those	  patients.	  
	  
Methods:	  A	  retrospective	  chart	  study	  was	  conducted	  using	  the	  records	  for	  current	  
OTR	  patients	  referred	  to	  a	  specialized	  transplant	  dermatology	  clinic	  from	  1991	  to	  
2012.	  The	  data	  reasons	  for	  referral	  as	  well	  as	  outcomes	  in	  terms	  of	  diagnosis	  of	  
premalignant/malignant	  cutaneous	  lesions.	  
	  
Results:	  353	  patient	  records	  were	  recorded.	  81	  patients	  were	  diagnosed	  with	  a	  total	  
of	  491	  premalignant/malignant	  skin	  lesions.	  The	  reason	  for	  referral	  most	  closely	  
associated	  with	  lesion	  diagnosis	  was	  “lesion	  of	  concern/skin	  cancer”,	  with	  26%	  of	  
these	  patients	  being	  diagnosed	  within	  6	  months,	  and	  50%	  of	  them	  diagnosed	  over	  
follow-­‐up.	  37%	  of	  the	  patients	  referred	  for	  “rash/acne”	  were	  diagnosed	  with	  BCC	  
within	  6	  months	  of	  referral.	  17.8%	  of	  patients	  who	  are	  referred	  for	  “acne/rash”	  
eventually	  get	  diagnosed	  with	  malignant/premalignant	  lesions.	  	  
	  
Conclusions:	  This	  is	  the	  first	  study	  to	  examine	  the	  link	  between	  the	  reason	  for	  
referral	  of	  OTR	  to	  specialized	  dermatologic	  care	  and	  patient	  outcomes.	  Our	  results	  
show	  that	  despite	  the	  well-­‐established	  increased	  risk	  of	  OTR	  for	  skin	  malignancies,	  
there	  are	  still	  significant	  delays	  in	  timely	  referrals	  and	  eventual	  diagnoses.	  A	  more	  
efficient	  risk-­‐stratification	  and	  referral	  process	  will	  likely	  lead	  to	  better	  patient	  
outcomes	  and	  a	  decreased	  tumor	  burden	  for	  these	  patients.	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Presently,	  there	  are	  more	  than	  170,000	  solid	  organ	  transplant	  recipients	  (OTR)	  
living	  in	  the	  US	  alone[1].	  This	  large	  number	  is	  attributable	  to	  significant	  
improvements	  in	  transplantation	  medicine,	  from	  surgical	  advances	  allowing	  more	  
transplantations	  to	  be	  carried	  out	  successfully,	  to	  improved	  medical	  management	  of	  
OTR	  resulting	  in	  their	  increased	  survival	  rates.	  This	  is	  of	  particular	  interest	  to	  
dermatologists,	  because	  of	  OTR’s	  increased	  risk	  for	  skin	  malignancies,	  particularly	  
NMSC.	  	  
	  
Nonmelanoma	  Skin	  Cancers	  (NMSC)	  are	  the	  most	  common	  malignancies	  in	  
humans[2,	  3].	  NMSC	  can	  be	  of	  two	  types:	  Basal	  Cell	  Carcinoma	  (BCC),	  a	  malignant	  
neoplasm	  that	  may	  derive	  from	  hair	  follicle	  stem	  cells,	  and	  Squamous	  Cell	  
Carcinoma	  (SCC),	  a	  malignant	  neoplasm	  deriving	  from	  epidermal	  keratinocytes.	  SCC	  
have	  a	  higher	  potential	  for	  metastasis	  than	  BCC	  [2],	  although	  BCC	  can	  invade	  locally	  
and	  cause	  significant	  tissue	  damage.	  Another	  difference	  between	  SCC	  and	  BCC	  is	  in	  
their	  pathogenesis:	  while	  BCC	  are	  thought	  to	  arise	  de	  novo,	  SCC	  are	  more	  likely	  the	  
result	  of	  the	  evolution	  of	  precursor	  lesions	  such	  as	  Actinic	  Keratoses	  (AK)	  [3].	  The	  
latter	  are	  neoplasms	  arising	  from	  epidermal	  keratocytes	  that	  become	  cytologically	  
aberrant	  after	  prolonged	  exposure	  to	  UV	  radiation.	  Of	  165	  cutaneous	  SCCs,	  
Mittelbronn	  et	  al.	  found	  that	  82·4%	  either	  arose	  within	  (26·7%)	  or	  in	  close	  





were	  contiguous	  with	  AKs[5],	  and	  in	  a	  review	  of	  the	  literature,	  Glogau	  concluded	  
that	  the	  risk	  of	  progression	  of	  AK	  to	  SCC	  was	  0.025–16%[6]	  
	  
	  
Organ	  transplant	  recipients	  (OTR)	  have	  been	  shown	  to	  have	  an	  increased	  risk	  for	  
malignancies	  [8].	  Of	  those,	  skin	  cancers	  are	  the	  most	  frequent	  [9][8][7][10].	  While	  
the	  prevalence	  of	  rare	  lesions	  such	  as	  melanoma,	  Kaposi’s	  sarcoma	  and	  Merkel	  cell	  
carcinomas	  are	  increased	  as	  compared	  to	  the	  general	  population,	  NMSC	  account	  for	  






OTR	  share	  the	  same	  risk	  factors	  for	  skin	  cancers	  as	  the	  rest	  of	  the	  general	  
population.	  Predisposing	  factors	  include	  light	  skin,	  eyes,	  and	  hair	  and	  tendency	  to	  
get	  sunburned.	  The	  major	  carcinogen	  for	  the	  development	  of	  NMSC	  is	  exposure	  to	  
UV	  radiation,	  especially	  UVB,	  as	  suggested	  by	  the	  fact	  that	  lesions	  almost	  exclusively	  
occur	  on	  sun-­‐exposed	  areas,	  and	  occur	  more	  frequently	  in	  sunnier	  countries.	  In	  
addition	  to	  that,	  it	  has	  been	  shown	  that	  even	  for	  patients	  who	  develop	  NMSC,	  sun	  
protection	  and	  avoidance	  after	  diagnosis	  of	  the	  first	  lesion	  decreases	  the	  likelihood	  
of	  subsequent	  ones	  [11].	  However,	  an	  important	  added	  risk	  factor	  that	  is	  specific	  to	  








An	  important	  risk	  factor	  for	  development	  of	  NMSC	  in	  OTR	  is	  age.	  This	  has	  been	  
demonstrated	  both	  in	  Kidney	  Transplant	  Recipients	  (KTR)	  and	  Heart	  Transplant	  
Recipients	  (HTR),	  where	  the	  risk	  ratio	  was	  12	  times	  higher	  for	  patients	  who	  
received	  their	  grafts	  above	  the	  age	  of	  55	  when	  compared	  to	  patients	  who	  received	  
their	  grafts	  before	  the	  age	  of	  34[12].	  The	  higher	  incidence	  of	  NMSC	  in	  HTR	  as	  
compared	  to	  KTR	  was	  originally	  thought	  to	  be	  due	  to	  increased	  levels	  of	  
immunosuppression	  in	  HTR,	  but	  recent	  data	  have	  shown	  that	  the	  older	  age	  of	  most	  
HTR	  at	  transplantation	  is	  more	  likely	  contributory	  [13]	  [10]	  [12]-­‐	  indeed,	  the	  
dosages	  of	  immunosuppression	  at	  the	  time	  the	  first	  NMSC	  was	  diagnosed	  was	  
similar	  for	  both	  HTR	  and	  KTR	  [11].	  It	  is	  therefore	  more	  likely	  that	  the	  increased	  
incidence	  of	  NMSC	  in	  HTR	  is	  because	  of	  the	  higher	  age	  at	  which	  HTRs	  get	  
transplanted	  compared	  to	  KTR.	  
	  
Time	  since	  transplantation	  
	  
Pharmacologic	  suppression	  of	  the	  immune	  system,	  which	  is	  essential	  to	  protect	  the	  
transplant	  against	  rejection,	  increases	  the	  risk	  of	  developing	  malignancies,	  
particularly	  cutaneous	  one.	  The	  duration	  of	  immunosuppression	  is	  positively	  
associated	  with	  the	  number	  of	  NMSC	  lesions	  OTR	  will	  develop.	  One	  piece	  of	  
evidence	  for	  this	  is	  that	  the	  number	  of	  lesions	  over	  the	  same	  follow-­‐up	  period	  tends	  
to	  be	  higher	  in	  KTR	  than	  HTR,	  [11]-­‐	  this	  could	  be	  due	  to	  the	  lower	  age	  of	  KTR	  at	  
transplantation,	  which	  means	  that	  they	  will	  have	  had	  a	  longer	  period	  of	  





NMSC	  increases	  steadily	  with	  time	  after	  transplantation.	  In	  the	  US,	  and	  Western	  
Europe,	  the	  incidence	  of	  NMSC	  at	  2,	  10	  and	  20	  years	  post-­‐transplant	  increase	  from	  





The	  incidence	  of	  NMSC	  has	  been	  reported	  to	  be	  higher	  in	  countries	  and	  regions	  with	  
higher	  exposure	  sunlight.	  In	  an	  Australian	  cohort,	  the	  cumulative	  incidence	  of	  NMSC	  
has	  been	  reported	  to	  be	  45%	  by	  10	  years	  after	  transplantation,	  and	  70%	  by	  20	  years	  
post-­‐transplantation[17].	  In	  the	  UK,	  by	  comparison,	  the	  mean	  annual	  risk	  for	  
developing	  NMSC	  was	  found	  to	  be	  3.27%	  for	  OTR	  less	  than	  5	  years	  post	  –transplant,	  
5.86%	  for	  OTR	  5-­‐10	  years	  post-­‐transplant,	  and	  11.1%	  more	  than	  10	  years	  post-­‐
transplantation,	  which	  is	  markedly	  lower	  than	  the	  Australian	  cohorts.	  [15]	  	  
	  
Type	  of	  transplant	  
	  
The	  type	  of	  transplant	  also	  influences	  the	  incidence	  of	  NMSC	  in	  OTRs.	  There	  is	  
evidence	  that	  Heart	  Transplant	  Recipients	  	  (HTR)	  have	  a	  two	  to	  fourfold	  increased	  
incidence	  of	  NMSC	  as	  compared	  to	  Kidney	  Transplant	  (HTR)	  [10],	  [13]	  [12]	  
	  
Type	  of	  tumor	  
	  
The	  ratio	  of	  SCC	  to	  BCC	  is	  4:1	  in	  the	  population	  at	  large.	  This	  ratio	  is	  reversed	  in	  





exposure,	  and	  the	  time	  elapsed	  in	  between	  follow-­‐up	  dermatologic	  appointments.	  
[8],	  [10].	  	  
The	  considerable	  acceleration	  of	  SCC	  incidence	  in	  SOTR	  is	  such	  that	  the	  diagnosis	  of	  
a	  first	  SCC	  has	  been	  shown	  to	  be	  highly	  predictive	  of	  multiple	  subsequent	  NMSC	  
within	  5	  years	  [11].	  Not	  only	  do	  these	  tumors	  occur	  with	  a	  higher	  incidence,	  they	  
are	  also	  clinically	  more	  aggressive	  in	  OTR	  than	  in	  the	  general	  population	  in	  terms	  of	  
growth,	  local	  recurrence	  and	  metastasis	  (the	  rate	  of	  metastasis	  is	  approximately	  
8%)[18,	  19].	  	  
Another	  important	  risk	  factor	  among	  OTR	  is	  pre-­‐transplant	  personal	  history	  of	  AK,	  
BCC,	  SCC	  or	  melanoma,	  which	  places	  the	  patient	  at	  a	  significantly	  higher	  risk	  for	  
developing	  post-­‐transplant	  skin	  cancer[20].	  
	  
Clinical	  Features	  	  
	  
Clinically,	  NMSC	  tend	  to	  appear	  on	  sun-­‐exposed	  area	  about	  8-­‐10	  years	  after	  
transplantation,	  and	  as	  described	  by	  Bouwes-­‐Bavinck,	  are	  often	  associated	  with	  
other	  keratotic	  lesions	  that	  can	  be	  confused	  with	  SCC,	  such	  as	  Actinic	  Keratoses,	  
Bowen’s	  disease,	  and	  Keratoacanthoma	  [20].	  Multiple	  Keratotic	  lesions	  have	  been	  
linked	  with	  an	  increased	  risk	  for	  SCC.	  Patients	  who	  have	  less	  than	  50	  keratotic	  
lesions	  have	  a	  4-­‐fold	  elevated	  risk	  of	  having	  an	  SCC,	  and	  patients	  with	  greater	  than	  
50	  keratotic	  lesions	  have	  a	  12-­‐fold	  elevated	  risk,	  both	  compared	  to	  patients	  with	  no	  





which	  sun-­‐exposed	  areas	  undergo	  actinic	  damage	  resulting	  in	  visible	  and	  sub-­‐
clinical	  lesions	  of	  epidermal	  dysplasia.	  
Compared	  to	  BCC,	  SCC	  are	  considered	  to	  be	  more	  aggressive	  in	  terms	  of	  growth,	  
recurrence,	  and	  ability	  to	  metastasize.	  The	  rate	  of	  local	  recurrence	  is	  13.4%,	  and	  
metastasis	  is	  5-­‐8%	  [21].	  A	  18.6%	  rate	  of	  extracutaneous	  tumors	  has	  been	  reported	  
for	  OTR	  diagnosed	  with	  SCC,	  which	  confirms	  previous	  reports	  that	  OTR	  diagnosed	  
with	  skin	  cancers	  have	  a	  higher	  overall	  tumor	  burden	  than	  others	  [22].	  
	  
	  
Management	  of	  NMSC	  in	  OTR	  
	  
The	  management	  of	  OTR	  risk	  for	  NMSC	  is	  best	  done	  in	  a	  multidisciplinary	  manner,	  
conjugating	  the	  care	  of	  the	  transplant	  physician	  with	  that	  of	  a	  specialized	  
dermatologist.	  The	  transplant	  dermatologist	  has	  not	  only	  a	  role	  to	  play	  in	  the	  
treatment	  of	  lesions,	  but	  also	  in	  preventive	  education,	  chemoprophylaxis,	  and	  




The	  most	  important	  element	  of	  patient	  education	  for	  OTR	  with	  regard	  to	  their	  skin	  
cancer	  risk	  is	  photo-­‐education.	  Sun	  avoidance	  and	  protection	  is	  the	  cornerstone	  of	  
any	  prevention	  program.	  The	  dermatologist’s	  role	  in	  this	  process	  is	  crucial,	  because	  
several	  studies	  have	  shown	  that	  OTR	  who	  have	  a	  dermatologist	  involved	  in	  their	  





recommendations.	  Ismail	  et	  al	  reported	  that	  among	  patients	  attending	  their	  
specialist	  OTR	  clinic,	  98%	  recalled	  receiving	  photo-­‐protection	  advice	  and	  95%	  
reported	  regular	  sunscreen	  use,	  compared	  with	  77%	  and	  67%,	  respectively,	  for	  
patients	  who	  did	  not	  have	  specialized	  dermatologic	  care	  [23].	  	  The	  dermatologist	  
working	  in	  an	  OTR	  clinic	  has	  an	  important	  role	  to	  play	  in	  encouraging	  all	  OTR	  to	  
apply	  sunscreen	  with	  sufficient	  sun	  protection	  factor	  daily,	  instead	  of	  only	  when	  sun	  
exposure	  is	  anticipated,	  and	  recommend	  that	  OTR	  avoid	  sun	  between	  the	  hours	  of	  
10	  am	  and	  2	  pm.	  OTRs	  should	  also	  avoid	  artificial	  exposure	  to	  UV	  radiation	  (tanning	  





The	  concept	  of	  field	  cancerization	  was	  first	  proposed	  by	  Slaughter	  et	  al	  in	  1953	  to	  
refer	  to	  histologically	  abnormal	  tissue	  adjacent	  to	  tumor	  tissue.	  Environmental	  
carcinogens	  influence	  whole	  areas	  of	  the	  skin	  surface	  leading	  to	  simultaneous	  
(usually	  actinic)	  damage	  of	  a	  large	  proportion	  of	  epithelial	  cells,	  thus	  contributing	  to	  
premalignant	  states	  within	  the	  entire	  exposed	  surface.	  	  The	  whole	  area	  has	  
accumulated	  enough	  mutations	  to	  be	  at	  much	  greater	  malignant	  potential,	  even	  
after	  the	  original	  tumor	  has	  been	  removed.	  Therefore,	  for	  OTR	  at	  high	  risk	  for	  
cancer	  development,	  these	  high-­‐risk	  areas	  must	  be	  eliminated,	  or	  at	  least	  controlled,	  
nonsurgically[24].	  Retinoid	  derivatives	  have	  been	  investigated	  and	  been	  
demonstrated	  to	  have	  some	  clinical	  use	  in	  preventing	  NMSC	  in	  OTR.	  Oral	  acitretin	  





controlled	  trials[25,	  26].	  The	  current	  guidelines	  recommend	  adjuvant	  
chemoprophylaxis	  for	  OTR	  at	  high	  risk	  for	  developing	  multiple,	  recurrent	  and	  
aggressive	  NMSC[27].	  The	  barrier	  to	  chemoprophylaxis	  is	  poor	  compliance	  due	  to	  
poor	  tolerability	  of	  systemic	  retinoid.	  Patients	  complain	  of	  mucocutaneous	  xerosis,	  
cheilitis	  and	  arthralgia	  and	  discontinue	  therapy.	  Upon	  discontinuation	  of	  the	  drug,	  a	  
rebound	  effect	  is	  observed,	  where	  SCC	  relapses	  occur.	  Therefore,	  chemoprophylaxis	  




After	  appropriate	  photoeducation	  about	  sun	  protection/avoidance	  and	  possible	  
chemoprophylaxis,	  OTR	  must	  be	  followed	  closely	  and	  routinely	  to	  screen	  them	  for	  
the	  development	  of	  cutaneous	  malignancies.	  To	  that	  end,	  a	  multidisciplinary	  clinic	  is	  
considered	  the	  best	  approach,	  providing	  maximum	  efficiency	  in	  scheduling	  
appointments	  and	  allowing	  for	  standardization	  of	  follow-­‐up	  intervals	  in	  conjunction	  
with	  the	  primary	  transplant	  team.	  It	  is	  recommended	  that	  all	  OTR	  undergo	  a	  full	  
body	  skin	  exam	  prior	  to	  transplantation	  to	  establish	  a	  baseline	  and	  to	  determine	  the	  
initial	  frequency	  at	  which	  the	  patient	  will	  be	  seen	  for	  screening.	  At	  each	  subsequent	  
visit,	  the	  patient	  must	  be	  screened	  and	  any	  lesions	  treated.	  In	  addition	  to	  that,	  the	  
dermatologist	  has	  a	  role	  to	  play	  in	  educating	  the	  OTR	  in	  self-­‐examination	  and	  
monitoring	  of	  changing	  skin	  lesions.	  Patients	  at	  risk	  for	  metastatic	  skin	  cancers	  
should	  be	  taught	  to	  do	  lymph	  node	  self-­‐	  exams.	  Such	  an	  approach	  facilitates	  early	  










Actinic	  Keratoses,	  consistent	  with	  the	  concept	  of	  field	  cancerization,	  represent	  pre-­‐
malignant	  lesions	  that	  have	  the	  potential	  of	  developing	  into	  SCC,	  and	  therefore	  
should	  be	  managed	  aggressively	  with	  therapies	  such	  as	  cryotherapy,	  or	  
Electrodessication	  and	  Curettage	  (ED&C).	  In	  high-­‐risk	  patients,	  it	  is	  not	  sufficient	  to	  
treat	  the	  lesion,	  but	  also	  to	  use	  prophylaxis	  on	  the	  potentially	  malignant	  
surrounding	  tissue.	  For	  this	  purpose,	  5-­‐FU	  or	  photodynamic	  therapy	  can	  be	  
used[28].	  	  
	  
Squamous	  Cell	  Carcinomas	  are	  graded	  into	  low-­‐risk	  and	  high	  risk,	  which	  influences	  
the	  way	  they	  are	  treated.	  Factors	  which	  make	  an	  SCC	  high-­‐risk	  include	  size,	  
multiplicity,	  recurrence,	  ulceration,	  presence	  of	  satellite	  lesion,	  high-­‐risk	  location	  
and	  histology[29].	  The	  options	  for	  low-­‐risk	  SCC	  include	  Mohs	  micrographic	  surgery,	  
traditional	  surgical	  excision,	  and	  ED&C	  for	  multiple	  lesions	  that	  cannot	  be	  excised	  
[24].	  High-­‐risk	  SCC	  requires	  more	  aggressive	  and	  early	  intervention.	  Mohs	  
micrographic	  surgery	  is	  the	  treatment	  of	  choice;	  however	  excision	  with	  post-­‐
operative	  margin	  assessment	  is	  also	  used.	  	  Adjuvant	  radiation	  therapy	  can	  be	  used	  
for	  surgical	  resections	  where	  the	  margins	  have	  not	  been	  found	  to	  be	  clear	  of	  
malignancy.	  





Goals	  of	  Study	  
It	  has	  been	  well-­‐documented	  that	  OTR	  are	  at	  an	  increased	  risk	  for	  cutaneous	  
malignancies.	  Therefore,	  a	  proactive	  approach	  is	  required	  in	  managing	  this	  health	  
risk,	  with	  preventative	  education,	  prevention,	  and	  surveillance	  being	  the	  
cornerstone	  of	  morbidity	  reduction.	  The	  optimal	  management	  of	  NMSC	  risk	  in	  OTR	  
requires	  a	  multidisciplinary	  approach,	  involving	  the	  transplant	  physician	  and	  
dermatological	  specialists.	  A	  proactive	  risk	  reduction	  model	  would	  reduce	  the	  
morbidity	  of	  skin	  cancers	  OTR	  through	  an	  optimal	  referral	  system	  whereby	  OTR	  
who	  are	  at	  highest	  risk	  for	  developing	  NMSC	  are	  referred	  to	  dermatologic	  care	  for	  
preventative	  measures	  and	  surveillance,	  in	  a	  timely	  fashion,	  allowing	  early	  
prophylactic	  interventions	  to	  decrease	  the	  patient’s	  potential	  tumor	  burden,	  as	  well	  
as	  early	  diagnosis	  and	  treatment	  of	  malignant	  lesions.	  Since	  dermatologists	  are	  the	  
most	  qualified	  at	  educating	  OTR	  about	  how	  to	  prevent	  skin	  cancer,	  and	  at	  
diagnosing	  malignant	  lesions,	  OTR	  should	  be	  sent	  for	  preventative	  screening	  when	  
they	  are	  identified	  to	  be	  at	  risk,	  rather	  than	  after	  malignant	  lesions	  are	  suspected	  by	  
a	  non-­‐dermatologist,	  leaving	  no	  window	  for	  prophylaxis.	  Within	  such	  a	  
multidisciplinary	  clinic	  model,	  a	  key	  component	  of	  care	  is	  the	  referral	  process	  from	  
non-­‐dermatologic	  providers	  to	  dermatologic	  care.	  The	  reason	  for	  which	  an	  OTR	  is	  
referred	  by	  a	  non-­‐dermatologist	  for	  dermatologic	  care	  has	  not	  been	  previously	  






The	  aim	  of	  our	  study	  is	  to	  examine	  the	  referral	  process	  for	  OTR	  to	  be	  sent	  for	  
specialized	  dermatologic	  care.	  	  We	  hypothesize	  that	  the	  reason	  for	  which	  an	  OTR	  is	  
referred	  for	  dermatologic	  care	  has	  a	  significant	  effect	  on	  his/her	  outcomes	  in	  terms	  
of	  NMSC	  diagnoses.	  	  We	  will	  look	  at	  the	  reasons	  for	  which	  OTR	  are	  being	  referred	  to	  
dermatologic	  care	  and	  compare	  their	  outcomes,	  in	  order	  to	  answer	  several	  research	  
questions:	  
1. What	  is	  the	  referral	  reason	  that	  yields	  the	  highest	  proportion	  of	  NMSC	  
diagnoses?	  
2. Which	  referral	  group	  bears	  the	  highest	  tumor	  burden?	  
3. Is	  the	  current	  referral	  process	  resulting	  in	  missed	  opportunities	  for	  early	  
NMSC	  prevention/surveillance?	  
	  






Materials	  and	  methods	  
We	  conducted	  a	  retrospective	  chart	  study,	  using	  patient	  records	  from	  the	  Yale	  
Transplant	  Dermatology	  Clinic,	  located	  in	  New	  Haven	  for	  patients	  referred	  from	  
2007	  to	  2012.	  The	  clinic	  specializes	  in	  the	  care	  of	  OTR	  referred	  by	  transplant	  
physicians	  for	  dermatologic	  evaluation	  and	  works	  in	  a	  multidisciplinary	  fashion	  
with	  transplant	  physicians	  to	  manage	  OTR	  risk	  for	  cutaneous	  malignancies	  or	  other	  
lesions.	  Upon	  admission	  into	  the	  clinic,	  data	  is	  recorded	  by	  the	  dermatologist	  on	  
dedicated	  input	  forms	  containing	  fields	  corresponding	  to	  factors	  for	  developing	  skin	  
cancer,	  general	  medical	  history,	  transplant	  history,	  as	  well	  as	  reason	  for	  referral.	  A	  
full	  body	  skin	  exam	  is	  then	  performed	  by	  the	  dermatologist	  during	  the	  initial	  visit.	  
Information	  about	  cutaneous	  lesions	  found	  for	  these	  patients	  is	  also	  recorded	  in	  the	  
paper	  charts,	  including	  biopsy	  reports,	  location,	  and	  date	  of	  diagnosis.	  Patients	  
referred	  to	  the	  clinic	  are	  followed	  up	  periodically	  after	  initial	  referral,	  with	  follow-­‐
up	  appointments	  scheduled	  according	  to	  clinical	  need.	  The	  medical	  records	  used	  for	  
the	  purpose	  of	  this	  study	  were	  in	  paper	  form.	  	  
	  
Data	  collection	  took	  place	  from	  May	  to	  August	  2012,	  during	  which	  353	  patient	  
records	  were	  reviewed.	  	  The	  protocol	  was	  submitted	  to	  the	  Human	  Investigations	  
Committee	  (IRB),	  and	  approval	  was	  obtained	  prior	  to	  data	  collection.	  (protocol	  
#1206010335)	  Two	  separate	  databases	  were	  created:	  the	  first	  one	  contained	  data	  





anonymity.	  	  The	  second	  database	  was	  created	  to	  record	  data	  about	  NMSC	  lesions	  
diagnosed	  on	  patients.	  For	  each	  AK,	  BCC,	  and	  SCC,	  an	  entry	  was	  created	  in	  the	  
database,	  containing	  the	  date	  of	  diagnosis,	  type	  of	  diagnosis	  and	  location	  on	  the	  
patient’s	  body.	  	  AK	  were	  diagnosed	  both	  clinically	  and	  by	  biopsy,	  whereas	  BCC	  and	  
SCC	  were	  always	  diagnosed	  using	  a	  biopsy.	  The	  two	  databases	  were	  linked	  to	  allow	  
each	  NMSC	  lesion	  record	  to	  be	  traced	  back	  to	  the	  subject	  on	  whom	  it	  was	  diagnosed.	  	  
	  
In	  order	  to	  assess	  the	  impact	  on	  referral	  reasons	  and	  outcomes,	  reason	  for	  referral	  
was	  divided	  into	  5	  categories,	  namely	  “skin	  screening”,	  “rash	  or	  acne”,	  “lesion	  of	  
concern”,	  “unknown”	  or	  “other”.	  “Skin	  screening”	  describes	  referrals	  where	  no	  
specific	  lesion	  has	  been	  identified	  by	  the	  referring	  provider	  but	  he/she	  deemed	  that	  
the	  patient	  needed	  specialized	  dermatological	  care	  due	  to	  their	  risk	  for	  cutaneous	  
malignancies.	  ”Rash	  or	  Acne”	  describes	  referrals	  where	  a	  non-­‐malignant	  lesion	  has	  
been	  identified	  by	  the	  referring	  provider.	  “Lesion	  of	  concern”,	  on	  the	  other	  hand,	  
entails	  a	  lesion	  which	  the	  referring	  provider	  suspects	  might	  be	  skin	  cancer.	  	  
“Unknown”	  describes	  patients	  for	  which	  the	  “reason	  for	  referral”	  field	  was	  left	  
empty	  in	  the	  intake	  form,	  while	  “other”	  describes	  a	  referral	  reason	  outside	  of	  the	  4	  
other	  categories.	  	  	  
Statistical	  analysis	  focused	  on	  comparing	  variables	  of	  OTR	  who	  ended	  up	  being	  
diagnosed	  with	  a	  NMSC	  with	  those	  who	  did	  not.	  Patient	  variables	  were	  summarized	  
as	  mean	  and	  standard	  deviation	  for	  continuous	  variables,	  or	  frequency	  and	  





OTR	  who	  ended	  up	  being	  diagnosed	  with	  malignant/premalignant	  lesions	  vas	  those	  
who	  never	  being	  positive.	  	  
Reason	  for	  referral	  was	  one	  of	  the	  variables	  compared	  between	  the	  two	  groups.	  This	  
analysis	  enables	  us	  to	  discern	  which	  referral	  reasons	  were	  more	  likely	  to	  result	  in	  
diagnoses	  of	  AK,	  BCC	  and	  SCC	  as	  opposed	  to	  those	  who	  are	  were	  not.	  	  
We	  also	  compared	  the	  time	  elapsed	  between	  transplantation	  and	  first	  visit	  for	  
patients	  who	  were	  diagnosed	  with	  AK/BCC/SCC	  and	  those	  who	  remained	  skin	  
cancer-­‐free	  throughout	  their	  follow-­‐up	  time.	  This	  gives	  us	  pertinent	  information	  as	  
to	  how	  timely	  referrals	  might	  affect	  skin	  cancer	  outcomes.	  
Similar	  analyses	  were	  carried	  out	  to	  compare	  OTR	  who	  were	  diagnosed	  with	  AK,	  
BCC,	  SCC	  within	  6	  months	  of	  their	  first	  visit	  to	  those	  who	  are	  not.	  .	  The	  reason	  why	  
we	  specifically	  examined	  these	  patients	  was	  that	  they	  would	  have	  most	  likely	  
benefitted	  from	  an	  earlier	  referral.	  
	  We	  also	  compared	  the	  tumor	  burden	  across	  referral	  categories.	  This	  will	  allow	  us	  to	  
discern	  any	  referral	  groups	  bearing	  a	  disproportionately	  large	  tumor	  burden,	  which	  
is	  useful	  in	  terms	  of	  risk-­‐stratification	  and	  targeted	  interventions	  to	  reduce	  
morbidity.	  
Chi-­‐square	  test	  or	  t	  test	  were	  used	  as	  appropriate.	  All	  the	  statistical	  analyses	  were	  
performed	  using	  SAS	  9.3	  (SAS	  Institute	  Inc.,	  Cary,	  NC).	  Significance	  level	  was	  p	  <	  
0.05,	  two-­‐sided.	  	  
	  
	  





Table	  3:	  	  Dermatologic	  History	  
Table	  2:	  Transplant	  History	  
Results	  
Age	  and	  sex	  distribution	  
A	  total	  of	  353	  records	  were	  input	  into	  
the	  database.	  224	  were	  male	  and	  127	  
female.	  The	  mean	  age	  was	  54.1	  (std	  
deviation	  15.1).	  	  
Transplant	  History	  
A	  majority	  of	  the	  patients	  (179,	  or	  50.7%)	  were	  
KTR	  followed	  by	  HTR	  (82,	  or	  23.2%).	  There	  
were	  55	  patients	  with	  liver	  transplants,	  
accounting	  for	  15.6%	  of	  the	  sample.	  17	  
patients	  (4.8%)	  had	  more	  than	  1	  transplants.	  
For	  16	  patients	  (4.5%),	  the	  type	  of	  transplant	  
was	  not	  recorded.	  	  
Dermatologic	  History	  
The	  majority	  of	  patients	  (273	  patients,	  or	  77.3)	  
had	  no	  prior	  dermatologic	  history	  upon	  
admission	  to	  the	  clinic.	  However,	  26	  patients	  
(7.4%)	  had	  a	  history	  of	  BCC,	  25	  (7.1%)	  had	  a	  
history	  of	  SCC,	  and	  12	  (3.4%)	  had	  a	  history	  of	  
SCC	  in	  situ.	  
Demographics	   N,	  (%),	  	  
Age*	   54.1±	  15.1	  
Gender	   	  
	  	  	  Male	  	   224	  (63.5)	  
	  	  	  Female	   127	  (36.0)	  
Transplant	  Hx	   	  
Transplant	  type	   N,	  (%)	  
Kidney	  only	   179	  (50.7)	  
Kidney	  plus	  other	   17	  (4.8)	  
Heart	   82	  (23.2)	  
Liver	   55	  (15.6)	  
Pancreas	   3	  (0.9)	  
Lungs	   1	  (0.3)	  
Other/unknown	   16	  (4.5)	  
Derm	  History	   N,	  (%)	  
No	  history	  	   273	  (77.3)	  
Hx	  of	  AK	   27	  (7.7)	  
Hx	  of	  BCC	   26	  (7.4)	  
Hx	  of	  SCC	   25	  (7.1)	  
Hx	  of	  SCC	  in	  Situ	   12	  (3.4)	  
Hx	  of	  Melanoma	   5	  (1.4)	  
Hx	  of	  Atypical	  Nevi	   3	  (0.9)	  
Hx	  of	  Cutaneous	  
warts	  
36	  (10.2)	  
Hx	  of	  Genital	  warts	   4	  (1.1)	  





Table	  4:	  Reason	  for	  referral	  
Reason	  for	  referral	  
The	  referral	  reason	  was	  recorded	  for	  most	  patients,	  with	  only	  4	  patients	  (0.01%)	  
with	  missing	  referral	  information.	  The	  most	  common	  reason	  why	  patients	  were	  
referred	  to	  the	  clinic	  was	  for	  skin	  screening	  
(159	  patients,	  45%),	  followed	  closely	  by	  
“Rash/Acne”	  (140	  patients,	  or	  39.7%).	  There	  
was	  a	  considerable	  group	  referred	  for	  lesion	  
suspicious	  for	  cancer	  (34	  or	  9.6%).	  
	  
NMSC	  diagnoses	  
Among	  the	  353	  patients,	  81	  were	  diagnosed	  with	  
one	  or	  more	  malignant/premalignant	  lesions.	  50	  
(14.2%)	  were	  eventually	  diagnosed	  with	  one	  or	  
more	  AK,	  44	  (12.5%)	  were	  diagnosed	  with	  one	  or	  
more	  BCC,	  and	  70	  (19.8%)	  were	  diagnosed	  with	  one	  
or	  more	  SCC.	  	  
As	  shown	  in	  table	  5,	  19	  patients	  were	  diagnosed	  
with	  AK	  within	  6	  months	  of	  their	  first	  visit	  to	  the	  
clinic.	  16	  were	  diagnosed	  with	  BCC,	  12	  with	  SCC	  and	  
11	  with	  SCC	  in	  situ.	  
	  
Reason	  for	  referral	   N,	  (%)	  
Skin	  screening	   159(45.0)	  
Rash/Acne	   140(39.7)	  
Lesion	  of	  concern	   34	  (9.6)	  
Unknown	   4	  (0.01)	  
Other	   1(0.0)	  
Lesion	   N	  (%)	  
AK	   50	  (14.2)	  




Lesion	   N	  (%)	  
AK	  	   19	  (5.3)	  
BCC	   16	  (4.8)	  
SCC	  	   12	  (3.4)	  
SCC	  in	  situ	   11	  (3.1)	  
Table	  5:	  NMSC	  diagnoses	  
Table	  6:	  diagnoses	  within	  6	  





Exclusion	  of	  certain	  data	  fields	  
Some	  variables	  were	  collected	  from	  the	  intake	  forms,	  e.g.	  family	  history	  of	  cancer,	  
use	  of	  sun	  barriers/sunscreen	  had	  many	  missing	  values	  due	  to	  the	  information	  not	  
being	  present	  on	  the	  forms,	  and	  therefore	  were	  excluded	  from	  data	  analysis.	  Those	  
variables	  were	  not	  directly	  related	  to	  our	  hypothesis	  and	  therefore	  their	  exclusion	  




OTR	  who	  develop	  malignancies	  versus	  others:	  	  
	  
Bivariate	  analysis	  was	  performed	  to	  compare	  OTR	  who	  ended	  up	  being	  diagnosed	  
with	  NMSC	  with	  those	  who	  never	  get	  diagnosed.	  This	  allowed	  us	  to	  correlate	  
specific	  variables	  with	  subsequent	  diagnosis	  of	  NMSC.	  
	  
	  	  	  	  	  	  Table	  7:	  comparing	  OTR	  who	  get	  diagnosed	  v/s	  those	  who	  do	  not	  
	  	  













p	  value	   P=0.0002	   P=0.001	   P=0.001	   	  
N	   50	   44	   52	   272	  
Referral	  categories	   	   	   	   	  
Skin	  screening	   20	  (40.8%)	   15	  (34.1%)	   18	  (35.3%)	   123	  (47.1%)	  
Rash	  or	  Acne	   15	  (30.6%)	   17	  (38.6%)	   16	  (31.4%)	   115	  (44.1%)	  
Lesion	  of	  concern	  or	  
skin	  cancer	  
13	  (26.5%)	   11	  (25.0%)	   15	  (29.4%)	   17	  (6.5%)	  
Unknown	   1	  (2.0%)	   1	  (2.3%)	   1	  (2.0%)	   6	  (2.3%)	  





The	  data	  in	  table	  7	  can	  be	  used	  to	  assess	  which	  referral	  reasons	  were	  more	  likely	  to	  
yield	  positive	  diagnoses	  for	  the	  lesions	  listed	  (AK,	  BCC,	  SCC).	  The	  percentages	  in	  
brackets	  indicate	  the	  distribution	  of	  referral	  reasons	  for	  patients	  diagnosed	  with	  a	  
particular	  lesion.	  	  For	  example,	  40.8%	  of	  patients	  who	  got	  diagnosed	  with	  AK	  were	  
referred	  for	  skin	  screening,	  as	  compared	  to	  47.1%	  who	  were	  without	  any	  
malignancy	  referred	  for	  same	  reason.	  	  From	  the	  table,	  it	  is	  clear	  that	  patients	  who	  
end	  up	  being	  diagnosed	  with	  AK/BCC/SCC	  were	  more	  likely	  referred	  due	  to	  lesion	  




OTR	  who	  are	  diagnosed	  with	  malignancies	  within	  6	  months	  of	  



















Total number 19 16 19 272 
      Skin screening  9 (47.3)  5 (31.3) 8 (42.1) 123 (47.1) 
      Rash/Acne 3 (15.8) 6 (37.5) 3 (15.8) 115 (44.1) 
      Lesion of 
concern/skin cancer 7 (36.8) 4 (25.0) 7 (36.8) 
17 (6.5) 
      Unknown 0 1 (6.2) 1 (5.3)  6 (2.3) 




The	  above	  table	  shows	  the	  comparison	  of	  patients	  who	  were	  diagnosed	  with	  NMSC	  
within	  6	  months	  of	  referral	  v/s	  those	  who	  aren’t.	  Of	  the	  50	  patients	  who	  were	  





diagnosed	  with	  AK	  at	  the	  clinic,	  19	  (38%)	  had	  their	  AK	  diagnosed	  within	  6	  months	  
of	  their	  initial	  visit	  at	  the	  clinic.	  Of	  the	  44	  patients	  who	  were	  diagnosed	  with	  BCC	  
during	  their	  followup,	  36.3%,	  were	  diagnosed	  within	  6	  months	  of	  referral,	  and	  of	  the	  
52	  patients	  diagnosed	  with	  SCC/SCC	  in	  situ,	  44%	  were	  diagnosed	  within	  6	  months	  
of	  referral.	  	  	  
Patients	  diagnosed	  with	  a	  lesion	  within	  6	  months	  were	  mostly	  likely	  to	  be	  referred	  
for	  “lesion	  of	  concern/Skin	  cancer”	  comparing	  to	  those	  no	  NMSC	  diagnosed	  in	  first	  6	  
months,,	  since	  	  those	  referrals	  made	  up	  only	  6.5%	  of	  the	  “lesion	  negative”	  group,	  
while	  making	  up	  36.8%	  of	  AK	  diagnoses	  (p<0.001),	  25%	  of	  the	  BCC	  diagnoses	  
(p=0.03)	  and	  36.8%	  of	  the	  SCC	  diagnoses	  (p<0.001).	  It	  is	  however	  interesting	  to	  
note	  that	  a	  considerable	  proportion	  of	  cancerous	  or	  pre-­‐cancerous	  diagnoses	  were	  
made	  within	  6	  months	  for	  patients	  who	  were	  referred	  for	  rash/acne	  (non-­‐cancer	  
referral),	  particularly	  for	  BCC.	  These	  patients	  made	  up	  37.5%	  of	  those	  who	  were	  
diagnosed	  with	  a	  BCC	  within	  six	  months,	  making	  them	  the	  most	  represented	  referral	  
reason	  for	  early	  diagnoses	  of	  BCC.	  
A	  total	  of	  3	  patients	  were	  diagnosed	  with	  an	  invasive	  form	  of	  skin	  cancer	  (BCC/SCC),	  
who	  had	  been	  referred	  for	  Rash/Acne.	  This	  is	  a	  concerning	  finding,	  because	  these	  
skin	  cancer	  diagnoses	  are	  incidental,	  reflecting	  the	  fact	  that	  these	  patients	  would	  










For	  the	  purpose	  of	  our	  study,	  we	  define	  the	  tumor	  burden	  as	  the	  number	  of	  
malignant/premalignant	  lesions	  diagnosed,	  including	  AK,	  BCC	  and	  SCC.	  	  The	  total	  
number	  of	  AK	  lesions	  diagnosed	  for	  the	  patients	  was	  192,	  total	  number	  of	  BCC	  was	  
106,	  while	  the	  total	  number	  of	  SCC/SCC	  IS	  is	  193.	  Therefore	  the	  SCC:BCC	  ratio	  in	  our	  






As	  shown	  in	  table	  9,	  patients	  referred	  for	  lesion	  of	  concern/skin	  cancer	  contributed	  
far	  more	  to	  the	  tumor	  burden,	  across	  tumor	  categories	  (for	  AK,	  BCC	  and	  SCC)	  than	  
any	  other	  referral	  reason,	  even	  though	  they	  only	  accounted	  for	  9.6%	  of	  the	  sample	  
size.	  	  Another	  noteworthy	  observation	  is	  that	  even	  though	  there	  were	  fewer	  patients	  
referred	  for	  Acne/Rash	  than	  for	  Skin	  Screening	  (39.7%	  of	  total	  patients	  vs	  45.0%	  
respectively),	  the	  tumor	  burden	  across	  both	  groups	  is	  comparable	  for	  BCC	  and	  SCC,	  







SCC/SCC In situ 
N/n=193/52 
    Skin Screening 1.0 (1.0 to 6.0) 1.0 (1.0 to 6.0) 5.0 (3.0 to 8.0) 
Acne/Rash 2.0 (1.0 to 14.0) 1.0 (1.0 to 5.0) 5.0 (2.0 to 9.0) 
Lesion of 
concern/Cancer 3.0 (1.0 to 37.0) 3.0 (1.0 to 7.0) 5.0 (2.0 to 22.0) 
Other/UK 2.0 (1.0 to 3.0) 8.0 9.0 (6.0 to 10.0) 








Time	  between	  transplant	  and	  first	  visit	  versus	  lesion	  diagnosis	  
	  
Table	  10:	  Time	  from	  transplant	  to	  first	  visit	  for	  patients	  diagnosed	  with	  NMSC	  vs	  
patients	  negative	  for	  NMSC	  
	  [Data	  is	  presented	  as	  mean	  (SD)	  upper	  panel,	  and	  median	  (min,	  max)	  lower	  panel.	  
	  
Table	  10	  compares	  the	  time	  elapsed	  from	  transplant	  to	  first	  visit.	  Across	  referral	  
categories,	  patients	  who	  were	  diagnosed	  with	  AK/BCC/SCC	  the	  mean	  time	  from	  
transplantation	  to	  first	  dermatological	  visit	  is	  higher	  than	  those	  who	  are	  not	  
diagnosed	  with	  such	  lesions.	  For	  example,	  for	  patients	  referred	  for	  rash/acne,	  the	  
mean	  time	  from	  transplant	  to	  first	  visit	  for	  patients	  who	  were	  diagnosed	  with	  a	  
lesion	  was	  8.4	  years	  as	  opposed	  to	  5.0	  years	  for	  patients	  who	  were	  not	  diagnosed	  
with	  any	  lesions.	  
Outcomes	   Skin	  
screening	  
	  
Rash	  or	  Acne	  
	  
Lesion	  of	  











3.5	  (0	  to	  66)	  
N=143	  
5.6	  (6.7)	  
2.6	  (0.1	  to	  34.9)	  
N=125	  
5.4	  (7.1)	  
2.3	  (0	  to	  27.5)	  
N=31	  
7.5	  (11.6)	  





2.8	  (0	  to	  66)	  
N=110	  
5.0	  (6.2)	  
1.8	  (0.1	  to	  30.1)	  
N=102	  
4.8	  (5.9)	  
2.2	  (0	  to	  19.8)	  
N=14	  
2.7	  (3.0)	  




with	  AK,	  BCC	  
or	  SCC	  
8.9	  (10.1)	  




5.9	  (0.2	  to	  34.9)	  
N=23	  
5.9	  (8.2)	  
2.3	  (0.1	  to	  
27.5)	  
N=17	  







Because	  OTR	  are	  treated	  by	  multiple	  physicians	  and	  have	  many	  comorbid	  
conditions	  along	  with	  their	  well-­‐established	  increased	  risk	  for	  NMSC,	  it	  is	  clear	  that	  
a	  proactive	  rather	  than	  reactive	  approach	  to	  NMSC	  prevention,	  surveillance,	  and	  
treatment	  is	  needed.	  	  The	  multi-­‐disciplinary	  system	  of	  care	  whereby	  dermatologic	  
specialists	  collaborate	  closely	  with	  transplant	  physicians	  and	  surgeons	  has	  been	  
described	  as	  a	  superior	  model	  for	  such	  proactive	  care	  to	  be	  delivered	  [29].	  Within	  a	  
multi-­‐specialty	  context,	  the	  referral	  process	  is	  a	  crucial	  component	  of	  quality	  of	  care,	  
because	  it	  constitutes	  the	  liaison	  between	  the	  different	  specialties,	  and	  specifically	  
in	  this	  case,	  between	  the	  non-­‐dermatologist	  and	  the	  dermatologic	  specialist.	  Our	  
study	  is	  the	  first,	  to	  our	  knowledge,	  to	  examine	  the	  reason	  for	  referral	  of	  patients	  
referred	  to	  a	  multidisciplinary	  dermatology	  clinic	  specializing	  in	  the	  care	  of	  OTR	  and	  
examine	  its	  relationship	  with	  patient	  outcomes.	  
	  
Patient	  demographics	  	  
There	  were	  significantly	  more	  males	  in	  our	  OTR	  sample	  than	  females	  (63.5%	  
males).	  This	  is	  not	  unexpected,	  since	  there	  are	  more	  male	  OTR	  than	  females;	  a	  study	  
of	  OTR	  patients	  in	  Queensland	  Australia	  had	  a	  similar	  percentage	  of	  male	  patients	  of	  
61.3%	  [30].	  The	  overall	  incidence	  of	  NMSC	  diagnoses	  was	  22.9%.	  This	  number	  is	  
known	  to	  increase	  with	  lower	  latitudes.	  As	  comparisons,	  the	  cumulative	  incidence	  of	  





[31]compared	  to	  30-­‐52%	  in	  the	  UK.	  Our	  incidence	  is	  lower	  than	  the	  UK	  cohort[32],	  
but	  that	  can	  be	  explained	  by	  our	  shorter	  median	  follow-­‐up	  time.	  	  
	  
	  
Reason	  for	  referral	  and	  NMSC	  diagnosis	  




Analysis	  of	  our	  data	  revealed	  that	  the	  referral	  reason	  that	  was	  most	  closely	  
associated	  with	  cancer	  diagnoses	  among	  OTR	  was	  “lesion	  of	  concern/skin	  cancer”.	  
Of	  the	  34	  OTR	  who	  were	  referred	  under	  this	  category,	  17	  (50%),	  were	  eventually	  
diagnosed	  with	  either	  AK,	  BCC	  or	  SCC.	  9	  patients	  (26%)	  in	  this	  category	  were	  
diagnosed	  with	  SCC	  within	  6	  months	  of	  their	  first	  visit,	  highlighting	  the	  urgency	  with	  
which	  they	  needed	  to	  be	  seen.	  In	  figure	  1,	  each	  bar	  represents	  the	  percentage	  of	  
NMSC	  diagnoses	  attributable	  to	  each	  referral	  category.	  As	  expected,	  “lesion	  of	  










































Figure	  1:	  NMSC	  
diagnoses(%)	  across	  
referral	  groups	  (bars	  for	  
“unknown”	  and	  “other”	  
excluded	  because	  of	  very	  






diagnosis	  is	  lower	  than	  for	  AK,	  BCC,	  and	  SCC.	  This	  is	  a	  graphical	  illustration	  of	  the	  
higher	  risk	  for	  these	  OTR	  to	  be	  diagnosed	  with	  these	  lesions.	  	  
	  
	  
	  Based	  on	  figure	  1,	  in	  terms	  of	  risk-­‐stratification,	  patients	  referred	  for	  “lesion	  of	  
concern/skin	  cancer”	  constitute	  a	  relatively	  higher-­‐risk	  group	  among	  which	  
diagnosis	  of	  NMSC	  is	  particularly	  likely.	  This	  is	  important	  for	  two	  reasons:	  first,	  it	  
validates	  the	  non-­‐dermatologist’s	  suspicion	  that	  a	  particular	  OTR	  is	  at	  risk	  for	  skin	  
cancer.	  	  Second,	  it	  raises	  the	  concern	  that	  these	  patients	  should	  have	  been	  referred	  
earlier,	  for	  surveillance,	  in	  a	  more	  proactive,	  rather	  than	  reactive,	  manner.	  Indeed,	  
the	  data	  in	  table	  7	  shows	  that	  while	  this	  group	  only	  makes	  up	  9.6%	  of	  our	  sample	  
size,	  it	  bears	  the	  largest	  share	  of	  the	  total	  tumor	  burden	  compared	  to	  all	  the	  other	  
referral	  groups.	  It	  also	  bears	  the	  largest	  share	  of	  early	  SCC	  diagnoses:	  26%	  of	  
patients	  under	  this	  category	  were	  diagnosed	  with	  an	  SCC	  within	  6	  months	  of	  their	  
first	  visit,	  as	  compared	  to	  5.7%	  of	  patients	  who	  were	  referred	  for	  “skin	  screening”.	  
This	  highlights	  the	  need	  for	  better	  risk-­‐stratification,	  using	  current,	  well-­‐established	  
risk	  factors	  for	  NMSC	  in	  OTR,	  and	  early	  referral	  of	  those	  high-­‐risk	  patients	  to	  
dermatologic	  care	  for	  effective	  photoeducation,	  prevention	  and	  surveillance.	  
Numerous	  studies	  have	  shown	  that	  both	  knowledge	  of	  the	  importance	  of	  
photoprotection	  and	  compliance	  with	  photoprotective	  measures	  are	  consistently	  
deficient	  among	  OTR	  [33]	  [34,	  35].	  Seukeran	  and	  colleagues	  have	  proposed	  that	  
these	  attitudes	  might	  be	  due	  to	  the	  lack	  of	  exposure	  to	  dermatologic	  care	  for	  those	  
OTR[36].	  Several	  other	  studies	  have	  shown	  that	  the	  intervention	  of	  a	  dermatologist	  





patient	  photoeducation	  [23].	  The	  data	  gathered	  in	  our	  study	  emphasizes	  the	  need	  
for	  earlier	  intervention	  in	  this	  group	  of	  patients,	  who	  would	  benefit	  from	  a	  timelier	  
referral.	  Effective	  photoeducation	  and	  prevention	  among	  this	  group	  could	  achieve	  a	  
considerable	  reduction	  in	  the	  overall	  tumor	  burden	  (table	  7).	  	  	  
	  
Patients	  referred	  for	  rash/acne	  
	  
As	  opposed	  to	  OTR	  referred	  for	  “lesion	  of	  concern/skin	  cancer”,	  those	  under	  
“Acne/Rash”	  have	  been	  referred	  for	  lesions	  that	  were	  not	  suspected	  to	  be	  malignant,	  
indicating	  a	  relatively	  lower	  level	  of	  suspicion	  for	  NMSC	  from	  the	  referring	  provider.	  
140	  OTR	  in	  our	  study	  fell	  under	  this	  referral	  category,	  out	  of	  whom	  25	  (17.8%)	  
ended	  up	  being	  diagnosed	  with	  either	  AK,	  BCC	  or	  SCC.	  3	  patients	  in	  this	  group	  were	  
diagnosed	  with	  SCC	  within	  6	  months	  of	  their	  first	  visit	  to	  the	  clinic,	  and	  6	  were	  
diagnosed	  with	  BCC	  within	  6	  months	  of	  their	  first	  visit	  to	  the	  clinic.	  While	  those	  
patients	  constitute	  a	  small	  percentage	  of	  the	  total	  number	  of	  people	  referred	  for	  
rash/acne,	  those	  early	  diagnoses	  are	  particularly	  worrisome	  because	  NMSC	  were	  
not	  suspected	  in	  these	  patients.	  They	  might	  not	  have	  been	  referred	  to	  dermatologic	  
care	  had	  their	  referring	  physician	  not	  believed	  they	  had	  a	  rash	  or	  acne,	  which	  could	  
have	  resulted	  in	  delayed	  diagnosis	  and	  therefore	  increased	  morbidity	  for	  these	  
patients.	  The	  high	  proportion	  (17.8%)	  of	  patients	  referred	  for	  a	  rash/acne	  who	  
eventually	  get	  diagnosed	  with	  AK/BCC/SCC	  during	  their	  follow-­‐up	  at	  the	  clinic	  
raises	  the	  question	  of	  whether	  these	  patients	  should	  have	  been	  more	  effectively	  
risk-­‐stratified	  and	  referred	  for	  dermatologic	  care	  even	  in	  the	  absence	  of	  their	  





the	  data	  in	  table	  10	  which	  shows	  that	  for	  these	  patients,	  the	  time	  elapsed	  from	  
transplant	  to	  the	  first	  dermatological	  visit	  is	  positively	  associated	  with	  an	  increased	  
risk	  for	  them	  to	  be	  diagnosed	  with	  AK/BCC/SCC.	  
	  
Strengths	  and	  Weaknesses	  of	  the	  Study	  
	  
The	  strength	  of	  the	  study	  is	  the	  large	  number	  of	  OTR	  followed	  as	  well	  as	  follow	  up	  
time	  (median	  follow	  up	  time	  is	  36	  months),	  which	  allows	  us	  to	  look	  at	  the	  short	  and	  
long-­‐term	  outcomes	  of	  patients	  referred	  to	  the	  clinic.	  The	  presence	  of	  individual	  
record	  lesions	  and	  pathology	  reports	  prevents	  recall	  bias	  for	  AK/BCC/SCC	  
diagnoses.	  However,	  since	  our	  study	  looked	  at	  prevalent	  patients	  only,	  we	  might	  
encounter	  survivor	  bias,	  i.e,	  if	  patients	  with	  NMSC	  are	  more	  or	  less	  likely	  to	  die,	  our	  
patient	  sample	  will	  not	  be	  representative	  of	  all	  OTR.	  Another	  possible	  source	  of	  bias	  
might	  stem	  from	  our	  changing	  awareness	  about	  UV	  exposure	  and	  NMSC	  prevention	  
over	  the	  years,	  and	  how	  this	  information	  is	  disseminated	  to	  OTR,	  which	  might	  
induce	  bias	  when	  comparing	  patients	  who	  had	  organs	  transplanted	  at	  different	  
points	  in	  the	  past.	  Lastly,	  the	  patient	  data	  we	  collected	  were	  from	  1	  institution	  only,	  




In	  conclusion,	  analysis	  of	  the	  electronic	  medical	  records	  of	  353	  OTR	  referred	  to	  a	  





Skin	  Screening,	  140	  for	  Acne/Rash	  and	  34	  for	  Lesion	  of	  Concern/Skin	  Cancer.	  The	  
overall	  incidence	  of	  skin	  cancer	  amongst	  those	  patients	  was	  high,	  at	  22.9%,	  but	  that	  
number	  was	  still	  lower	  than	  published	  skin	  cancer	  rates	  in	  OTR	  in	  different	  studies.	  
Further	  analysis	  reveals	  that	  most	  of	  the	  tumor	  burden	  for	  those	  patients	  was	  borne	  
by	  the	  patients	  referred	  for	  lesion	  of	  concern,	  even	  though	  they	  are	  far	  less	  
numerous	  than	  patients	  in	  the	  other	  referral	  categories.	  Among	  the	  140	  OTR	  
referred	  for	  acne/rash,	  9	  were	  diagnosed	  with	  invasive	  NMSC	  within	  six	  months	  of	  
their	  first	  visit,	  and	  25	  were	  eventually	  diagnosed	  with	  skin	  cancer	  over	  follow-­‐up	  
appointments.	  These	  observations	  lead	  to	  the	  conclusion	  that	  despite	  the	  fact	  that	  
risk	  factors	  for	  OTR	  to	  develop	  NMSC	  are	  well-­‐documented	  within	  the	  literature,	  
patients	  are	  still	  experiencing	  delayed	  or	  missed	  referrals	  to	  specialized	  
dermatologic	  care,	  resulting	  in	  sub-­‐optimal	  outcomes.	  This	  paves	  the	  way	  for	  better	  
risk-­‐stratification	  and	  referral	  strategies	  to	  ensure	  timely	  and	  appropriate	  referrals,	  
which	  would	  reduce	  the	  overall	  tumor	  burden	  for	  OTR.	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